Yiling Pharmaceutical Ciprofloxacin Hydrochloride Tablets Passed the Consistency Evaluation

　　Pharmaceutical Network November 7th, November 6th, Eling Pharmaceuticals issued a notice that the company received the State Drug Administration approved the issuance of the "drug supplementary application approval", the drug through the quality and efficacy of generic drugs consistent evaluation (hereinafter referred to as "consistency evaluation") Yaling Pharmaceuticals is the first in the country to pass the consistency evaluation of the variety 　　Ciprofloxacin hydrochloride tablets are anti-infective drugs used to treat or prevent confirmed or highly suspected sensitive bacterial infections and belong to the National Health Insurance Catalog (2019 edition) and the Essential Medicines Catalog (2018 edition) ciprofloxacin tablets were first developed by Bayer (Bayer) and were listed in Germany on January 30, 1987, and the product, named Ciprobay, was announced by the State Administration of Food Supervision and Administration as a reference for consistency evaluation to evaluate the product consistency of the product for the reference agent using Bayer's production and listing of ciprofloxacin tablets in Germany Through the detailed study of the quality properties of the reference preparation, the key prescription factors and process parameters affecting the were studied to ensure the stable and controllable quality of the products, and the bioequial tablets of the subjects were tested on fasting and post-meal bioequivalence, and the bioequivalent of the hydrochloric acid cyclic sand saccharin tablets of Ling pharmaceutical sand was confirmed to be bioequivalent to the original drug In summary, the hydrochloric acid cyclopia tablets developed by Eling Pharmaceuticals reached quality and efficacy consistent with the original drug a total of 108 salt acid cyclocicosis tablets production approval, as of the date of this announcement, only Ealing Pharmaceutical research and development of citeopropyl sand flakes through the National Drug Administration consistency evaluation and approval.